Wellbutrin Claims and Topamax Claims on the Rise at Carey Danis & Lowe

By | Pharmaceutical litigation, Topamax, Uncategorized, Wellbutrin

Published October 31, 2012 by PR Web

St. Louis, MO (PRWEB) October 31, 2012

Wellbutrin Claims and Topamax Claims on the Rise at Carey Danis & LowePharmaceutical product liability lawyers at Carey Danis & Lowe have announced that they are undertaking an investigation into Wellbutrin claims. Attorneys at Carey Danis & Lowe are asking that individuals and families contact the law firm if they feel their child, or the child of a loved one, was born with a congenital heart defect due to the use of Wellbutrin during pregnancy.

Wellbutrin is a drug manufactured by GlaxoSmithKline, and is used in to treat patients suffering from depression as well as seasonal affective disorder (SAD), attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has classified Wellbutrin as a Pregnancy Category C drug.

Wellbutrin allegedly causes birth defects include oral defects, congenital heart defects, Craniosynostosis, Omphalocele, and Persistent Pulmonary Hypertension of the Newborn (PPHN).

In addition, lawyers at Carey, Danis and Lowe are taking cases related to the use the use of Topamax. Prescribed to patients suffering from epilepsy and migraine headaches, Topamax is a drug manufactured by Ortho-McNeil-Janssen Pharmaceuticals Inc. Allegedly, Topamax can cause congenital oral defects in unborn children. The FDA has categorization Topamax as a Pregnancy Category D drug. Potential oral birth defects caused by Topamax include the development of a cleft lip and cleft palette.

In past pharmaceutical product liability cases, attorneys at Carey Danis & Lowe have aided plaintiffs in winning cases against pharmaceutical giants like GlaxoSmithKline and Ortho-McNeil-Janssen Pharmaceuticals Inc.

If a newborn baby has suffered birth defects allegedly caused by exposure in the womb to either Wellbutrin or Topamax, contact an attorney at Carey Danis & Lowe at 800.721.2519, or submit a claims form about filing a Wellbutrin lawsuit or a Topamax lawsuit.

Antidepressant Wellbutrin Linked to Birth Defects

By | Pharmaceutical litigation, Uncategorized, Wellbutrin

Published October 23, 2012 by

Antidepressant Wellbutrin Linked to Birth DefectsManufactured by pharmaceutical giant GlaxoSmithKline, Wellbutrin is an antidepressant drug that has been linked to congenital birth defects. The U.S. Food and Drug Administration (FDA) approved the antidepressant medication Wellbutrin (bupropion) in order to treat depression.

Due to the increasing occurrences of life-threatening and life-altering birth defects connected with the use of Wellbutrin in pregnant mothers, the FDA has categorized Wellbutrin as a pregnancy category C drug. Unlike many antidepressants on the market that block serotonin, Wellbutrin is categorized as a norepinephrine and dopamine re-uptake inhibitor (NDRI).

Wellbutrin birth defects include, but are not limited to, the following:

  • Cleft lip
  • Cleft palate
  • Congenital cardiac defects
  • Atrial Septal Defects (ASD)
  • Ventricular Septal Defects (VSD)
  • Persistent Pulmonary Hypertension of the Newborn(PPHN)
  • Craniosynostosis
  • Omphalocele

In 2010, a Wellbutrin study was published in the American Journal of Obstetrics and Gynecology that pointed to data showing a significant link between the use of Wellbutrin by a pregnant woman, especially during the first trimester of pregnancy, and the development of congenital birth defects, in particular cardiac complications and malformations.

Termination of Wellbutrin use during pregnancy will most certainly benefit an unborn child as a result of Wellbutrin’s connection to birth defects. However, discontinued use of an antidepressant drug by a pregnant woman must be discussed with a physician in order to weigh the risks of continued use on the unborn child and terminated use on the expectant mother.

It is also important to note that following pregnancy, if a nursing mother decides to begin use of Wellbutrin, such a decision is important to discuss with a physician. It has been understood that Wellbutrin is a drug that can present itself in breast milk, and therefore, can lead to injurious health effects on a newborn.

If your newborn has suffered from birth defects correlated to exposure to Wellbutrin in the womb, submit your claim to an experienced pharmaceutical litigation lawyer at Carey Danis & Lowe. Also, contact a pharmaceutical product liability attorney at Carey Danis & Lowe at 800.721.2519 for a free legal consultation about filing a Wellbutrin lawsuit. It is important to hold GlaxoSmithKline accountable for their negligence to inform the public about Wellbutrin’s link to the development of life-threatening congenital birth defects.

Our lawyers at Carey Danis & Lowe are committed to providing you the legal support and counsel you need to win a Wellbutrin lawsuit and receive compensation for your pain, suffering, and financial losses.